Posted by Michael Wonder on 03 Jun 2021
Dermavant submits new drug application to FDA for tapinarof cream for the treatment of adults with plaque psoriasis
3 June 2021 - New drug application is supported by positive data from the Phase 3 PSOARING 1 and PSOARING 2 pivotal efficacy trials and interim results from the PSOARING 3 long-term safety study.
Dermavant Sciences today announced that it has submitted a new drug application to the U.S. FDA for tapinarof for the treatment of mild, moderate and severe plaque psoriasis in adult patients.
